Sovleplenib is under clinical development by Hutchison MediPharma and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sovleplenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sovleplenib (HMPL-523) is under development for the treatment of hematological cancers such as relapsed and refractory Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, coronavirus disease 2019 (COVID-19), waldenstrom macroglobulinemia, mantle cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma and immunological diseases including autoimmune disorder, primary immune thrombocytopenia, Hodgkin and non-Hodgkin lymphoma, marginal zone B-cell lymphoma and autoimmune hemolytic anemia. It is administered orally as a tablet and suspension. The drug candidate targets spleen tyrosine kinase (Syk). It was also under development for acute myeloid leukemia, multiple sclerosis, lupus erythematosus and rheumatoid arthritis. The drug candidate is a new molecular entity (NME).
Hutchison MediPharma overview
Hutchison MediPharma (HMPL) carries out discovery, development and commercialization of therapeutics in oncology and autoimmune diseases. The company’s products include savolitinib, fruquintinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. It develops drug discovery technologies in molecular and cell biology, high throughput screening, genomics and informatics to support research and development projects. HMPL’s research and development programs comprise gene-targeted and cell-based screening assays, ligand-dependent screening assays and signal transduction pathway screening assays. The company’s products serve in the fields of medicinal chemistry, pharmacology, oncology, cardiovascular and respiratory diseases, and antiviral treatments. It operates through its two offices in Pudong, China. HMPL is headquartered in Pudong, China.
For a complete picture of Sovleplenib’s drug-specific PTSR and LoA scores, buy the report here.